Bharat Biotech’s Covaxin highly efficacious, presents no safety concerns: Lancet study

Covaxin “induces a robust antibody response" two weeks after two doses are given, it said. “Covaxin’s Phase 3 efficacy results have been peer-reviewed and published in The Lancet. Another milestone for Indian science, not much more to be said,” tweeted Raches Ella, clinical lead, Covid-19 vaccines at Bharat Biotech.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wC4lyt
via IFTTT